- $287.39m
- $277.26m
- $4.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 18.06 | ||
| Price to Tang. Book | 18.06 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 63.55 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -119.9% | ||
| Return on Equity | -248.97% | ||
| Operating Margin | -1261.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.04 | n/a | 2.49 | 6.04 | 4.05 | 2.52 | 1.63 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Directors
- Shankar Musunuri CHM (57)
- Sanjay Subramanian CFO (45)
- Nirdosh Jagota SVP
- Vijay Tammara SVP (61)
- Kirsten Castillo IND (48)
- Prabhavathi Fernandes IND (72)
- Uday Kompella IND (54)
- Ramesh Kumar IND (65)
- Manish Potti IND (35)
- Junge Zhang IND (54)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- July 14th, 2006
- Public Since
- December 3rd, 2014
- No. of Shareholders
- 26
- No. of Employees
- 95
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 292,031,295
- Address
- 11 GREAT VALLEY PARKWAY, MALVERN, 19355
- Web
- https://ocugen.com/
- Phone
- +1 4843284701
- Contact
- Tiffany Hamilton
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for OCGN
Q3 2025 Ocugen Inc Earnings Release
Similar to OCGN
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Ocugen share price?
As of Today at 22:24 UTC, shares in Ocugen are trading at $0.98. This share price information is delayed by 15 minutes.
How has the Ocugen share price performed this year?
Shares in Ocugen last closed at $0.98 and the price had moved by -31.18% over the past 365 days. In terms of relative price strength the Ocugen share price has underperformed the S&P500 Index by -39.13% over the past year.
What are the analyst and broker recommendations for Ocugen?
The overall consensus recommendation for Ocugen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ocugen dividend yield?
Ocugen does not currently pay a dividend.
Does Ocugen pay a dividend?
Ocugen does not currently pay a dividend.
When does Ocugen next pay dividends?
Ocugen does not currently pay a dividend.
How do I buy Ocugen shares?
To buy shares in Ocugen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ocugen?
As of the previous close price of $0.98, shares in Ocugen had a market capitalisation of $287.39m.
Where are Ocugen shares listed?
Here are the trading details for Ocugen:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: OCGN
What kind of share is Ocugen?
Based on an overall assessment of its quality, value and momentum Ocugen is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ocugen share price forecast for 2025?
The analyst consensus target price for shares in Ocugen is $6.50. That is 560.5% above the last closing price of $0.98.
Analysts covering Ocugen currently have a consensus Earnings Per Share (EPS) forecast of -$0.23 for the next financial year.
Find out moreWhat is the trend in the Ocugen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ocugen. Over the past six months, its share price has outperformed the S&P500 Index by +11.36%.
As of the last closing price of $0.98, shares in Ocugen were trading +17.77% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ocugen PE Ratio?
The Ocugen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ocugen?
Ocugen's management team is headed by:
- Shankar Musunuri - CHM
- Sanjay Subramanian - CFO
- Nirdosh Jagota - SVP
- Vijay Tammara - SVP
- Kirsten Castillo - IND
- Prabhavathi Fernandes - IND
- Uday Kompella - IND
- Ramesh Kumar - IND
- Manish Potti - IND
- Junge Zhang - IND